Open access
Sep 2026
The epidemiological impact and effectiveness of herpes zoster vaccination among older and pharmacologically immunocompromised adults: a population-based observational study
Summary Background Australia used the live attenuated herpes zoster vaccine (ZVL, Zostavax®) for 70–79 year-old adults in its National Immunisation Program from 2016. In November 2023 this was replaced with the recombinant adjuvanted herpes zoster vaccine (RZV, Shingrix) and eligibility expanded to include adults ≥65 y...
J. Reekie, Sandrine Stepien, J. Li-Kim-Moy et al.
· The Lancet Regional Health -... · 0 citations